EICHOR
● Active Not Recruiting
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin Lymphoma · Sponsor: Hoffmann-La Roche
About this study
This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparison with a commonly used regimen in this participant population, rituximab, gemcitabine and oxaliplatin (R-GemOx).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (52)
| City of Hope Cancer Center | Duarte, California, United States | — |
| St. Luke's Hospital | Chesterfield, Missouri, United States | — |
| Ascension Seton Infusion Center | Austin, Texas, United States | — |
| MD Anderson Cancer Center | Houston, Texas, United States | — |
| Hospital Aleman | Buenos Aires, Argentina | — |
| Instituto Alexander Fleming | Buenos Aires, Argentina | — |
| FUNDALEU | Buenos Aires, Argentina | — |
| Hospital Italiano de Buenos Aires | Ciudad Autonoma Buenos Aires, Argentina | — |
| Hospital Erasto Gaertner | Curitiba, Paraná, Brazil | — |
| Hospital das Clinicas - UFRGS | Porto Alegre, Rio Grande do Sul, Brazil | — |
| Hospital das Clínicas FMRP-USP | Ribeirão Preto, São Paulo, Brazil | — |
| Hospital Sao Jose | São Paulo, São Paulo, Brazil | — |
+ 40 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05171647